Tempus AI, Inc. (NASDAQ:TEM) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Tempus AI, Inc. (NASDAQ:TEM) have earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $56.00.

TEM has been the subject of a number of recent analyst reports. Guggenheim initiated coverage on Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 target price for the company. Wolfe Research started coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their target price for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Loop Capital boosted their price target on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, October 15th. Finally, Bank of America raised their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th.

Insider Buying and Selling at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 187,655 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total value of $7,044,568.70. Following the sale, the chief executive officer now directly owns 9,557,283 shares of the company’s stock, valued at approximately $358,780,403.82. This represents a 1.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the transaction, the insider now directly owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. This represents a 2.39 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 845,041 shares of company stock valued at $35,125,473.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors have recently made changes to their positions in the company. NEA Management Company LLC lifted its position in Tempus AI by 17.8% in the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after acquiring an additional 813,169 shares in the last quarter. Novo Holdings A S bought a new position in shares of Tempus AI during the second quarter valued at $142,605,000. Revolution Growth Management Company Inc. purchased a new stake in shares of Tempus AI during the second quarter valued at $128,133,000. ARK Investment Management LLC increased its holdings in Tempus AI by 355.0% in the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock worth $134,604,000 after buying an additional 1,855,459 shares in the last quarter. Finally, Alphabet Inc. bought a new stake in Tempus AI in the 2nd quarter worth about $54,289,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Down 3.6 %

TEM opened at $33.87 on Tuesday. Tempus AI has a one year low of $22.89 and a one year high of $79.49. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The firm’s 50 day simple moving average is $50.06.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.